p.88 抽出テキスト

432. Megaly M, Schmidt CW, Dworak MW, Garberich R, Stanberry L, Sharkey S, et al. Diabetic patients who present with ST-elevation myocardial infarction. Cardiovasc Revasc Med 2022;38:89–93. https://doi.org/10.1016/j.carrev.2021.08.003 433. Burgess S, Juergens CP, Yang W, Shugman IM, Idris H, Nguyen T, et al. Cardiac mortality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction. Int J Cardiol 2021;323:13–18. https://doi.org/10.1016/j.ijcard.2020.08.021 434. Burgess SN, Juergens CP, Nguyen T, Leung M, Robledo KP, Thomas L, et al. Diabetes and incomplete revascularisation in ST elevation myocardial infarction. Heart Lung Circ 2021;30:471–480. https://doi.org/10.1016/j.hlc.2020.09.928 435. Ullah W, Saleem S, Zahid S, Sattar Y, Mukhtar M, Younas S, et al. Clinical outcomes of patients with diabetes mellitus and acute ST-elevation myocardial infarction following fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis. Expert Rev Cardiovasc Ther 2021;19:357–362. https://doi.org/10.1080/14779072.2021.1888716 436. Rakowski T, De Luca G, Siudak Z, Plens K, Dziewierz A, Kleczyński P, et al. Characteristics of patients presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA) in Poland: data from the ORPKI national registry. J Thromb Thrombol 2019;47:462–466. https://doi.org/10.1007/s11239-018-1794-z 437. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177. https://doi.org/10.1093/ eurheartj/ehx393 438. Tardif J-C, L’Allier PL, Fitchett DH. Management of acute coronary syndromes. Can J Diabetes 2018;42:S190–S195. https://doi.org/10.1016/j.jcjd.2017.10.029 439. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360: 2165–2175. https://doi.org/10.1056/NEJMoa0807986 440. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome: VERDICT randomized controlled trial. Circulation 2018;138:2741–2750. https://doi.org/10.1161/ CIRCULATIONAHA.118.037152 441. Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, et al. Timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes and clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv 2016;9: 2267–2276. https://doi.org/10.1016/j.jcin.2016.09.017 442. Martinón-Martínez J, Alvarez Alvarez B, Gonzalez Ferrero T, Garcia-Rodeja Arias F, Otero Garcia O, Cacho Antonio C, et al. Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): evaluation of the new risk stratification in the NSTEACS European guidelines. Clin Res Cardiol 2021;110:1464–1472. https://doi.org/10.1007/s00392-021-01829-8 443. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AW, Badings EA, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet 2017;390:737–746. https://doi. org/10.1016/S0140-6736(17)31490-3 444. Li Y, Wang C, Nan Y, Zhao H, Cao Z, Du X, et al. Early invasive strategy for non-ST elevation acute coronary syndrome: a meta-analysis of randomized, controlled trials. J Int Med Res 2020;48:300060520966500. https://doi.org/10.1177/0300060520966500 445. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368 446. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105–113. https://doi.org/10.1016/ S2213-8587(14)70219-0 447. Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727. https://doi.org/ 10.1093/eurheartj/ehv134 448. Sattar N, McGuire DK. Pathways to cardiorenal complications in type 2 diabetes mellitus: a need to rethink. Circulation 2018;138:7–9. https://doi.org/10.1161/ CIRCULATIONAHA.118.035083 449. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614–1619. https://doi. org/10.2337/diacare.24.9.1614 450. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412–419. https://doi.org/10.1136/bmj.321.7258.412 451. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699–703. https://doi.org/10.2337/diacare.27.3.699 452. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005;96:1530–1536. https://doi.org/10.1016/ j.amjcard.2005.07.061 453. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot J-S, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association– European Society of Cardiology. Eur Heart J 2018;39:4243–4254. https://doi.org/10. 1093/eurheartj/ehy596 454. Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P, et al. Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol 2015;2015:743503. https://doi.org/10.1155/2015/743503 455. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999;22:1186–1190. https://doi. org/10.2337/diacare.22.7.1186 456. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation endproducts (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146–1155. https://doi.org/10.1016/j.ejheart.2007.09.009 457. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am College Cardiol 2008;52:1793–1799. https://doi.org/10.1016/j.jacc. 2008.07.062 458. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011;124:444–453. https://doi.org/10.1161/CIRCULATIONAHA.110. 014506 459. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005;28:612–616. https://doi.org/ 10.2337/diacare.28.3.612 460. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035–2038. https://doi.org/10.1001/jama.1979.03290450033020 461. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am College Cardiol 2000;35:1628–1637. https://doi.org/10.1016/S0735- 1097(00)00582-9 462. van Melle JP, Bot M, De Jonge P, De Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care 2010;33: 2084–2089. https://doi.org/10.2337/dc10-0286 463. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879–1884. https:// doi.org/10.2337/diacare.27.8.1879 464. Boonman-de Winter L, Rutten F, Cramer M, Landman M, Liem A, Rutten G, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012;55:2154–2162. https://doi.org/10.1007/ s00125-012-2579-0 465. Zareini B, Rørth R, Holt A, Mogensen UM, Selmer C, Gislason G, et al. Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol 2019;18:79. https://doi.org/10.1186/s12933-019- 0883-4 466. Centers for Disease Control and Prevention. Incidence of Newly Diagnosed Diabetes. https://www.cdc.gov/diabetes/data/statistics-report/newly-diagnosed-diabetes.html (21 April 2022) 467. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care 2017;40:671–678. https://doi.org/10.2337/dc16- 2016 468. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:54–65. https://doi.org/10.1002/ejhf.679 469. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585. https://doi.org/10. 1002/ejhf.813 470. Johansson I, Dahlström U, Edner M, Näsman P, Ryden L, Norhammar A. Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res 2018;15:494–503. https://doi.org/10. 1177/1479164118794619 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026